Barclays raised the firm’s price target on Icon to $355 from $325 and keeps an Overweight rating on the shares. The analyst says concerns over demand slowing were likely put to rest by the company’s commentary around requests for proposals accelerating in Q4 and being driven by biotech improving and large pharma demand strength.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ICLR: